Loading...
PEAR.Q logo

Pear Therapeutics, Inc.OTCPK:PEAR.Q Rapporto sulle azioni

Cap. di mercato US$142.0
Prezzo delle azioni
n/a
1Y-100.0%
7D0%
1D0%
Valore del portafoglio
​
Vista

Pear Therapeutics, Inc.

Report azionario OTCPK:PEAR.Q

Capitalizzazione di mercato: US$142.0

Pear Therapeutics (PEAR.Q) Panoramica del titolo

A commercial-stage healthcare company, develops and sells software-based medicines in the United States. Maggiori dettagli

PEAR.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria3/6
Dividendi0/6

Premi

I ricavi sono cresciuti del 201.7% nell'ultimo anno

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $142 )

Le azioni sono altamente illiquide

Gli ultimi report finanziari risalgono a più di un anno fa


PEAR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,966 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
474,966 investors already sharing narratives
View all narratives

Concorrenti di Pear Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Pear Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.000001
Massimo di 52 settimaneUS$0.02
Minimo di 52 settimaneUS$0.000001
Beta8.21
Variazione di 1 mese0%
Variazione a 3 mesi-99.00%
Variazione di 1 anno-99.97%
Variazione a 3 anni-100.00%
Variazione a 5 annin/a
Variazione dall'IPO-100.00%

Notizie e aggiornamenti recenti

Articolo di analisi • Apr 17

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Pear Therapeutics, Inc. ( NASDAQ:PEAR ) shareholders that were waiting for something to happen have been dealt a blow...

Recent updates

Articolo di analisi • Apr 17

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Pear Therapeutics, Inc. ( NASDAQ:PEAR ) shareholders that were waiting for something to happen have been dealt a blow...
Seeking Alpha • Aug 18

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue. They've laid off 9% of the workforce and operating expenses are down, and the focus is now mostly on the current line-up. Revenue guidance falls below our expectations at $15 million for 2022, so we're a little less convinced now since a venture is always a race against time. Published on the Value Lab 15/8/22 Pear Therapeutics (PEAR) is by far one of our worst performing ideas having been decimated in the SPAC boom. We quite agreed with the initial valuation given the blue skies in the markets and the treatment areas being so prevalent, but the markets, likely concerned also with reflexivity, were having none of it, thus a 80% decline. Now they've reported their Q2 results in their first year as a public company. From an execution point of view, we like what we see, but we're becoming aware of sluggishness in the realisation of agreements with payors, and since they are racing against time, despite the superb value add of the company to the health system and the substantial scope for value capture, we have our worries. Q2 Comments Let's start with the most important thing for any venture which is revenue. Q2 revenue was $3.3 million, 20% growth QoQ and 175% YoY, although the latter says nothing. This is annualising at around $12 million annually, and the guidance is for $15 million annually with the expectation of further QoQ growth. Major wins with payors came in with prescriptions rising quickly to over 10k, and ASPs at over $1.3k. While revenue growth is good, it takes a while for health systems to add Pear products to their coverage list, so despite the good uptake, accelerating any faster is not very doable. The leads take a good while to convert. Therefore, it can be said that the current revenue growth falling below our hopes is mostly a timing issue, where interest has yet to be realised into payor agreements, but the problem with a venture is that timing is everything. The company has about $100 million in cash and cash equivalents to last them into the following quarters. The company previously guided to 2023 being the next year where dilution will occur, but hopefully cost controls have somewhat pushed that out to mitigate a slower than hoped revenue trajectory. Pear has laid off 9% of its workforce, meaning a couple dozen people. Expenses have actually fallen by a couple of percent QoQ, which is great in light of the growing revenue, and these expenses are expected to continue to fall QoQ. But it is coming at a cost. Currently the Somryst and the reSET products are the ones that are getting coverage, the former for insomnia and related conditions and the latter being for substance abuse. Now with the cost cuts, the management is saying definitively that it is going to put work on its pipeline on the backburner. In addition to reducing our workforce, we substantially reduced work on pipeline candidates, discovery programs, business development, and our dual platforms. We didn't stop there. We also narrowed our commercial efforts to focus our resources on areas of highest coverage density, while de-prioritizing longer-term opportunities for the time being. As a result of the restructuring, we expect to reduce our operating expenses by approximately $28 million over 18 months. We expect to spend less in Q3 than we did in Q2, and we expect to spend less in Q4 than we did in Q3. Corey McCann, CEO of PEAR
Seeking Alpha • Aug 03

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Pear Therapeutics' (NASDAQ:PEAR) opioid use disorder prescription digital therapeutic will be provided to Core Behavioral Health centers in the Tampa Bay, Fla., area. Cove will offer the reSET-O product in English and Spanish. reSET-O is a prescription cognitive behavioral therapy that is used as an adjunct to outpatient treatment. In June, a study showed that use of reSET-O led to a reduction in inpatient stays.
Seeking Alpha • May 21

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that. As a digital company, they are pushing their own dashboard which seems to be picking up traction and creates some leverage potential for economies of scale and scope. ASPs are higher than we modeled still but will decline as rebates bring net prices down, but this would be concomitant with larger contracts and a good thing. Still early days, so who knows how long it will go, but the current cash position let us see till 2023 before more dilution.
Seeking Alpha • Apr 04

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Pear delivered well for the FY despite only being a post-revenue company for part of it. Covered lives are developing fast, and prescription numbers have just started to ramp. 2022 will be a full year of performance, and the company is guiding to sharp increases in prescriptions. Fulfillment metrics look good, meaning that on the patient side things look good, so it's all about pushing with physicians now. Pear is too young to make precise estimates, but based on management statements, cash burn shouldn't deplete cash reserves till mid-2023 by which time we hope to see scaling.
Seeking Alpha • Jan 10

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Pear is a category creator of Digital Therapeutics (DTx), which means its applications are reimbursed at phenomenal rates by payors and other benefit providers. The addressable market in the US alone is massive with Pear's treatment areas, and Pear is first out the gate. They have already achieved excellent R&D results on a small cost-base, and a digital pharma model will likely have inherently strong economics. Risks are primarily to do with educating the market, which also paves the way for competitors. Still, we are happy with the valuation given the intersection of digital health and telemedicine, two areas which have already proven quite revolutionary.

Rendimenti per gli azionisti

PEAR.QUS Healthcare ServicesUS Mercato
7D0%4.7%0.6%
1Y-100.0%-21.5%20.1%

Ritorno vs Industria: PEAR.Q ha avuto una performance inferiore rispetto al US Healthcare Services che ha registrato un rendimento -21.5 % nell'ultimo anno.

Rendimento vs Mercato: PEAR.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20.1 % nell'ultimo anno.

Volatilità dei prezzi

Is PEAR.Q's price volatile compared to industry and market?
PEAR.Q volatility
PEAR.Q Average Weekly Movementn/a
Healthcare Services Industry Average Movement10.1%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di PEAR.Q è stato volatile rispetto al mercato US.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di PEAR.Q nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2013200n/apeartherapeutics.com

Pear Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Pear Therapeutics con la sua capitalizzazione di mercato?
PEAR.Q statistiche fondamentali
Capitalizzazione di mercatoUS$142.00
Utili (TTM)-US$75.49m
Ricavi(TTM)US$12.69m
0.0x
Rapporto P/S
0.0x
Rapporto P/E

PEAR.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PEAR.Q Conto economico (TTM)
RicaviUS$12.69m
Costo del fatturatoUS$7.39m
Profitto lordoUS$5.30m
Altre speseUS$80.79m
Utili-US$75.49m

Ultimi utili riportati

Dec 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)-0.53
Margine lordo41.75%
Margine di profitto netto-594.70%
Rapporto debito/patrimonio netto89.7%

Come si è comportato PEAR.Q nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/05/27 05:40
Prezzo dell'azione a fine giornata2024/05/27 00:00
Utili2022/12/31
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Pear Therapeutics, Inc. è coperta da 6 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Michael ChernyBofA Global Research
Michael GormanBTIG
Marie ThibaultBTIG